DB05856ExperimentalSmall molecule
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
- Primary indication
- Investigated for use/treatment in metabolic disease.Curator reviewed
- Code names
- CPD 923
Which companies are running trials of CPD 923, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account